Therapeutics
Tacrine
Quick Links
Overview
Name: Tacrine
Synonyms: Cognex™
Chemical Name: 1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Approved)
Company: Pfizer, Shionogi Pharma
Background
Tacrine is a reversible acetylcholinesterase inhibitor. Originally developed by Warner-Lambert Co., tacrine was the first such drug to be introduced for the treatment of Alzheimer's disease in a range of countries in South America, Asia, Europe, Australia, and the United States in 1995 and 1996. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.
Last Updated: 08 May 2014
References
No Available References
Further Reading
No Available Further Reading
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.